Enhancing Cardiovascular Health through probiotic ingredients

Growing consumer focus on heart health creates new market opportunities as people take proactive steps to maintain their cardiometabolic well-being.

According to WHO, cardiovascular diseases (CVDs) cause around 17.9M death yearly at global level [1]. Growing evidence demonstrates how the combination of different metabolic comorbidities can affect the development of CVDs. Hence, the risk of cardiovascular disease (CVD) is not solely attributed to a single factor, but rather to a multifaceted condition. For instance, metabolic syndrome (MetS) is characterized by a combination of interrelated factors that directly elevate the risk of coronary heart disease.  It is mainly characterized by at least three concomitant hallmarks among dyslipidemia, high blood pressure, dysregulated glucose homeostasis, insulin resistance, and abdominal obesity [2]. Similarly, non-alcoholic fatty liver disease (NAFLD) is commonly recognized as the hepatic expression of metabolic syndrome [3].

Follow us on social media to make sure you don’t miss the next articles!

Sign up for the newsletter and get the full Focus On now!

    Born in 2022 as a spin-off of ROELMI HPC, we aim at becoming a leader in biotechnology thanks to all expertise gained in these years, with a huge number of projects fulfilled at worldwide level as well as the network of researchers, contributing to a multi-faced scientific approach.


    Silvia Castegnaro


    Product Manager